FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796001452> ?p ?o ?g. }

• W2796001452 endingPage "18366" @default.
• W2796001452 startingPage "18351" @default.
• W2796001452 abstract "// Akansha Jalota 1, 2 , Mukesh Kumar 1 , Bhudev C. Das 3, 4 , Ajay K. Yadav 3 , Kunzang Chosdol 2 and Subrata Sinha 1, 2 1 National Brain Research Centre, Manesar, Gurgaon-122051, India 2 Department of Biochemistry, All India Institute of Medical Sciences, New Delhi-110029, India 3 Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi-110007, India 4 Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida-201313, India Correspondence to: Subrata Sinha, email: sub_sinha@hotmail.com , subrata.sinha@nbrc.ac.in Keywords: BCNU; hypoxia; PGE2; chemosensitization; COX-2 inhibitor Received: July 05, 2017      Accepted: February 21, 2018      Published: April 06, 2018 ABSTRACT Hypoxia is a characteristic of solid tumors especially Glioblastoma and is critical to chemoresistance. Cancer stem cells present in hypoxic niches are known to be a major cause of the progression, metastasis and relapse. We tried to identify synergistic combinations of drugs effective in both hypoxia and normoxia in tumor cells as well as in cancer stem cells. Since COX-2 is over-expressed in subset of glioblastoma and is also induced in hypoxia, we studied combinations of a prototype Cyclooxygenase (COX-2) inhibitor, NS-398 with various drugs (BCNU, Temozolomide, 2-Deoxy-D-glucose and Cisplatin) for their ability to abrogate chemoresistance under both severe hypoxia (0.2% O 2 ) and normoxia (20% O 2 ) in glioma cells. The only effective combination was of NS-398 and BCNU which showed a synergistic effect in both hypoxia and normoxia. This synergism was evident at sub-lethal doses for either of the single agent. The effectiveness of the combination resulted from increased pro- apoptotic and decreased anti-apoptotic molecules and increased caspase activity. PGE 2 levels, a manifestation of COX-2 activity were increased during hypoxia, but were reduced by the combination during both hypoxia and normoxia. The combination reduced the levels of epithelial-mesenchymal transition (EMT) markers. It also resulted in a greater reduction of cell migration. While single drugs could reduce the number of gliomaspheres, the combination successfully abrogated their formation. The combination also resulted in a greater reduction of the cancer stem cell marker CD133. This combination could be a prototype of possible therapy in a tumor with a high degree of hypoxia like glioma." @default.
• W2796001452 created "2018-04-13" @default.
• W2796001452 creator A5035260455 @default.
• W2796001452 creator A5040917215 @default.
• W2796001452 creator A5052718719 @default.
• W2796001452 creator A5069308603 @default.
• W2796001452 creator A5079614531 @default.
• W2796001452 creator A5085925340 @default.
• W2796001452 date "2018-04-06" @default.
• W2796001452 modified "2023-10-01" @default.
• W2796001452 title "A drug combination targeting hypoxia induced chemoresistance and stemness in glioma cells" @default.
• W2796001452 cites W1030263894 @default.
• W2796001452 cites W1232771652 @default.
• W2796001452 cites W1817360198 @default.
• W2796001452 cites W1829367389 @default.
• W2796001452 cites W1969448148 @default.
• W2796001452 cites W1979583528 @default.
• W2796001452 cites W1979993490 @default.
• W2796001452 cites W1982319646 @default.
• W2796001452 cites W1984413324 @default.
• W2796001452 cites W1984470783 @default.
• W2796001452 cites W1989151297 @default.
• W2796001452 cites W1998188518 @default.
• W2796001452 cites W2005150545 @default.
• W2796001452 cites W2008854828 @default.
• W2796001452 cites W2013041233 @default.
• W2796001452 cites W2017901652 @default.
• W2796001452 cites W2021117623 @default.
• W2796001452 cites W2023868153 @default.
• W2796001452 cites W2027694152 @default.
• W2796001452 cites W2028593825 @default.
• W2796001452 cites W2032862134 @default.
• W2796001452 cites W2036264501 @default.
• W2796001452 cites W2038300246 @default.
• W2796001452 cites W2039075677 @default.
• W2796001452 cites W2040246237 @default.
• W2796001452 cites W2042705582 @default.
• W2796001452 cites W2045016464 @default.
• W2796001452 cites W2063523015 @default.
• W2796001452 cites W2063538683 @default.
• W2796001452 cites W2065176645 @default.
• W2796001452 cites W2066634650 @default.
• W2796001452 cites W2073417537 @default.
• W2796001452 cites W2078059722 @default.
• W2796001452 cites W2078422697 @default.
• W2796001452 cites W2078935333 @default.
• W2796001452 cites W2087408588 @default.
• W2796001452 cites W2088911689 @default.
• W2796001452 cites W2090057452 @default.
• W2796001452 cites W2090453807 @default.
• W2796001452 cites W2097669240 @default.
• W2796001452 cites W2097997344 @default.
• W2796001452 cites W2098174730 @default.
• W2796001452 cites W2099861108 @default.
• W2796001452 cites W2103177188 @default.
• W2796001452 cites W2105561184 @default.
• W2796001452 cites W2110711017 @default.
• W2796001452 cites W2111110000 @default.
• W2796001452 cites W2112245495 @default.
• W2796001452 cites W2117692326 @default.
• W2796001452 cites W2121205576 @default.
• W2796001452 cites W2123105952 @default.
• W2796001452 cites W2127558096 @default.
• W2796001452 cites W2128356791 @default.
• W2796001452 cites W2129883523 @default.
• W2796001452 cites W2133460396 @default.
• W2796001452 cites W2141879384 @default.
• W2796001452 cites W2143479101 @default.
• W2796001452 cites W2147794687 @default.
• W2796001452 cites W2152064969 @default.
• W2796001452 cites W2153476501 @default.
• W2796001452 cites W2157270051 @default.
• W2796001452 cites W2168556155 @default.
• W2796001452 cites W2261159156 @default.
• W2796001452 cites W2322816935 @default.
• W2796001452 cites W2399122692 @default.
• W2796001452 cites W2428522048 @default.
• W2796001452 cites W2430866285 @default.
• W2796001452 cites W2507916220 @default.
• W2796001452 cites W2570987484 @default.
• W2796001452 cites W2761714852 @default.
• W2796001452 cites W2914002569 @default.
• W2796001452 cites W4362218836 @default.
• W2796001452 doi "https://doi.org/10.18632/oncotarget.24839" @default.
• W2796001452 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5915077" @default.
• W2796001452 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29719610" @default.
• W2796001452 hasPublicationYear "2018" @default.
• W2796001452 type Work @default.
• W2796001452 sameAs 2796001452 @default.
• W2796001452 citedByCount "12" @default.
• W2796001452 countsByYear W27960014522019 @default.
• W2796001452 countsByYear W27960014522020 @default.
• W2796001452 countsByYear W27960014522021 @default.
• W2796001452 countsByYear W27960014522022 @default.
• W2796001452 countsByYear W27960014522023 @default.
• W2796001452 crossrefType "journal-article" @default.
• W2796001452 hasAuthorship W2796001452A5035260455 @default.
• W2796001452 hasAuthorship W2796001452A5040917215 @default.

• next